Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results.

Toth, Peter P

Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results. [electronic resource] - Journal of medical economics Jul 2017 - 749-751 p. digital

Publication Type: Journal Article

1941-837X

10.1080/13696998.2017.1327440 doi


Cardiovascular Diseases--economics
Cost-Benefit Analysis--methods
Humans
Hypolipidemic Agents--economics
Models, Econometric
PCSK9 Inhibitors
Quality-Adjusted Life Years
Risk Assessment